{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:56:05Z","timestamp":1791327365676,"version":"4.3.1"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Monoclonal antibodies (mAbs) targeting calcitonin gene\u2010related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. We report the data from two phase I studies assessing the safety, pharmacokinetics (PK), and pharmacodynamics of single and multiple administrations of erenumab in healthy subjects and patients with migraine. The results indicate that the PK profile of erenumab is nonlinear from 1 mg to 70 mg and the linear portion of the clearance from 70 mg to 210 mg is consistent with other human immunoglobulin G2 antibodies. Single doses of erenumab resulted in &gt;75% inhibition of capsaicin\u2010induced dermal blood flow, with no apparent dose\u2010dependency for erenumab \u226521 mg. Erenumab was generally well tolerated, with an acceptable safety profile, supporting further clinical development of erenumab for migraine prevention.<\/jats:p>","DOI":"10.1002\/cpt.799","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T08:36:40Z","timestamp":1500885400000},"page":"815-825","source":"Crossref","is-referenced-by-count":82,"title":["Phase I, Randomized, Double\u2010blind, Placebo\u2010controlled, Single\u2010dose, and Multiple\u2010dose Studies of Erenumab in Healthy Subjects and Patients With Migraine"],"prefix":"10.1111","volume":"103","author":[{"given":"Jan","family":"de Hoon","sequence":"first","affiliation":[{"name":"Center for Clinical Pharmacology University Hospitals of Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Van Hecken","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology University Hospitals of Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology University Hospitals of Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Yan","sequence":"additional","affiliation":[{"name":"Early Development, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Smith","sequence":"additional","affiliation":[{"name":"Early Development, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyun Sunny","family":"Chen","sequence":"additional","affiliation":[{"name":"Early Development, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Bautista","sequence":"additional","affiliation":[{"name":"Early Development, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science Amgen Ltd. Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Waksman","sequence":"additional","affiliation":[{"name":"Global Safety, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Vu","sequence":"additional","affiliation":[{"name":"Early Development, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Vargas","sequence":"additional","affiliation":[{"name":"Early Development, Amgen Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61729-2"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12154"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.982089"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12404"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00198-2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1991.hed3106365.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410160202"},{"key":"e_1_2_9_12_1","first-page":"159","article-title":"Neurovascular and molecular mechanisms in migraine headaches","volume":"5","author":"Moskowitz M.A.","year":"1993","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00037.2003"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399411002067"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.05.016"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-009-0112-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410368444"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398399"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61626-8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70128-0"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413517775"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70209-1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1489-4"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000771"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-007-9029-y"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.002"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2183-6"},{"key":"e_1_2_9_32_1","first-page":"1","article-title":"Phase 2, Randomized, double\u2010blind, placebo\u2010controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention [abstract]","volume":"36","author":"Tepper S.J.","year":"2016","journal-title":"Cephalalgia"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03543.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133868"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12704"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.224212"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00830.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03869.x"},{"key":"e_1_2_9_40_1","article-title":"Phase 1, randomized, parallel\u2010group, double\u2010blind, placebo\u2010controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy subjects [abstract]","author":"Hoon J.","year":"2017","journal-title":"AAN 2017 Annual Meeting"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0521-0"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:32:47Z","timestamp":1699363967000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/cpt.799"],"URL":"https:\/\/doi.org\/10.1002\/cpt.799","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}